
Topic
Clinical Evidence
Trial design, endpoints, real-world evidence, safety updates, and how evidence translates into market access.

Evidence· June 14, 2026 · 12 min read

Pipeline· June 13, 2026 · 15 min read
ClinicalTrials.gov competitor trial landscape: how launch teams map a crowded indication

Pipeline· June 13, 2026 · 12 min read
ClinicalTrials.gov by the numbers: 589K studies and a 58% Phase 3 results gap

Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials

Pipeline· June 12, 2026 · 9 min read
Retatrutide Phase 3: -28.3% body weight, 45% lose ≥30%, new UTI signal at ADA 2026
By Ran Chen#GLP-1#GIP/GLP-1#Clinical Evidence

Policy· June 10, 2026 · 10 min read
Inside 20 million FAERS reports: 57% serious, Enbrel leads, death in 1.9 million
By Ran Chen#FDA Approval#Drug Pricing#Clinical Evidence

Manufacturing· June 9, 2026 · 6 min read
The commercial ecosystem behind cell & gene therapy: ASGCT 2026 exhibitors mapped

Pipeline· June 8, 2026 · 11 min read
Botulinum toxin biosimilar pathway: the 351(k) race to challenge Botox
By Ran Chen#Biosimilars#FDA Approval#BLA Approval

Pipeline· June 8, 2026 · 10 min read
Veterinary JAK inhibitors Apoquel to Numelvi: FDA pathway compared

Pipeline· June 7, 2026 · 9 min read
Cytisinicline smoking cessation PDUFA preview: first new pharmacotherapy in 20 years
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence